Companies / Santa Cruz Biotechnology / p21 Waf1/Cip1 (F-5) FITC
Santa Cruz Biotechnology

p21 Waf1/Cip1 (F-5) FITC | Santa Cruz Biotechnology

mouse monoclonal IgG2b; p21 Waf1/Cip1 Antibody (F-5) is an IgG2b κ mouse monoclonal p21 Waf1/Cip1 antibody (also designated CIP1 antibody, WAF1 antibody, CDKN1A antibody or p21 antibody) that detects the p21 Waf1/Cip1 protein of mouse, rat and human origin by WB, IP, IF, IHC(P) and FCM. p21 Waf1/Cip1 Antibody (F-5) is available as both the non-conjugated anti-p21 Waf1/Cip1 antibody form, as well as multiple conjugated forms of anti-p21 Waf1/Cip1 antibody, including agarose, HRP, PE, FITC and multiple Alexa Fluor® conjugates. It is now well established that cyclins play a positive role in promoting cell cycle transitions via their ability to associate with and activate their cognate cyclin-dependent kinases (Cdks). Cdk2 associates with cyclins A, D and E, and has been implicated in the control of the G1 to S phase transition in mammals. p21 Waf1/Cip1, also designated Cip1 or WAF1, has been identified in cyclin A, cyclin D1, cyclin E and Cdk2 immunoprecipitates. The novel Cdk-interacting protein, p21 Waf1/Cip1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk 2, cyclin E-Cdk2, cyclin D1-Cdk4 and cyclin D2-Cdk4 complexes. Expression of p21 Waf1/Cip1 protein, which is identified using the p21 Waf1/Cip1 Antibody (F-5) in various research applications, is inducible by wildtype, but not mutant, p53. The mouse homolog of p21 Waf1/Cip1 is designated CAP20.

Reviews


No reviews yet

ABOUT THE COMPANY

Santa Cruz Biotechnology is a world leader in the development of products for the biomedical research market. Over the past 30+ years, the Company has focused on the ongoing development of research antibodies, siRNA and CRISPR Gene editing tools, biochemicals, labware and more recently has expanded into animal health care products. Santa Cruz Biotechnology has the highest commitment to quality and customer service.